Notably, combined treatment with USP7 inhibitor P5091 and EZH2inhibitors (GSK126, EPZ6438, and DZNep) augmented the inhibition of cell migration,invasion, and sphere-forming abilities in prostate cancer cells. Here, USP7 is linked to prostate carcinoma.